reports
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Mathijs Geerts Danau
- Wim Lewi
- Jacob Mekhael
argenx A catalyst rich year ahead
argenx is set for a catalyst rich year ahead and has five phase 3 trial results with its lead product, Vyvgart, as well as from the next in line product empasiprubart. Those programs are supported by positive proof of concept data, and successful phase 3 results could expand the company's commercial opportunity and bring it closer to its Vision 2030 target of having 50K patients on treatment. Going into 2026, we believe continued commercial momentum and pipeline expansion potential could bring a...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Mathijs Geerts Danau
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List How to start 2026?
How to start 2026? We have selected for the KBC Securities Dynamic Top Pick List 12 large-cap companies — AB InBev, Aedifica, Argenx, ASMi, Azelis, DEME, D'Ieteren, Shurgard, Sofina, Vopak, WDP, and Wolters Kluwer — along with 3 small and mid-cap names (under €1.5bn in market capitalization): Corbion, EVS, and IBA. So, going into 2026, we maintain a balanced approach in our Dynamic Top Pick List, featuring 8 cyclical and 6 defensive stocks, with a particular emphasis on value stocks that have b...
EVS EVS BROADCAST EQUIPMENT SA
DIE D'IETEREN SA
SOF SOFINA SA
ASM ASM INTERNATIONAL N.V.
IBAB ION BEAM APPLICATIONS SA
ROYAL VOPAK NV
AED AEDIFICA SA
CSM CORBION NV
ABI ANHEUSER-BUSCH INBEV SA/NV
ARGX ARGEN-X SE
WDP WAREHOUSES DE PAUW SCA
AZE AZELIS GROUP NV
DEME DEME GROUP NV
SHUR SHURGARD SELF STORAGE LIMITED
Argen X SE: 1 director
A director at Argen X SE sold 17,588 shares at 790.350EUR and the significance rating of the trade was 92/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Galapagos Receives Transparency Notifications from Bank of America
Galapagos Receives Transparency Notifications from Bank of America Mechelen, Belgium; November 26, 2025, 07:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transparency legislation1, Galapagos received transparency notifications on November 18 and November 19, 2025, from Bank of America Corporation indicating that it positively crossed the threshold of 5% of Galapagos’ voting rights on November 12, 2025 following an acquisition of Galapagos’ voting rights and equivalent financial instrumen...
Galapagos ontvangt transparantieverklaringen van Bank of America
Galapagos ontvangt transparantieverklaringen van Bank of America Mechelen, België; 26 november 2025, 07:30 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) heeft transparantieverklaringen ontvangen van Bank of America. Overeenkomstig de Belgische transparantiewetgeving1 ontving Galapagos op 18 en 19 november 2025 transparantieverklaringen van Bank of America Corporation. Daaruit blijkt dat Bank of America op 12 november 2025 de drempel van 5% van de stemrechten in Galapagos positief heeft overschreden na een verwerving van stemrechten en daarmee gelijkgestelde fin...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Wim Hoste
argenx Announces Results of Extraordinary General Meeting of Sharehold...
argenx Announces Results of Extraordinary General Meeting of Shareholders November 18, 2025 – 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Extraordinary General Meeting of shareholders held on November 18, 2025. The remuneration policy, which was the sole voting item on the agenda, was approved by the required majority of votes. The Company’s remuneration policy was approved by a 95.67% majority, with 91.1% of shar...
- Mathijs Geerts Danau
Hyloris Positive results for IV Aspirin, NDA will be submitted
Hyloris announced positive topline results from a pivotal study in healthy volunteers for IV aspirin. The trial achieved all its targets, enabling progression towards submission of a New Drug Application (NDA) in 2026 and expected approval in 2027. IV Aspirin is intended to be used in acute coronary syndrome and is part of Hyloris's CV portfolio, for which Hyloris needs to announce a commercial partner in the US. We model € 52m peak sales by 2037. We reiterate our HOLD and € 6 TP.
- Hilde Van Boxstael
- Lynn Hautekeete
- Mathijs Geerts Danau
- Wim Lewi
- Jacob Mekhael
- Emira Sagaama
- Hela Zarrouk
- Michael Foundoukidis
- Oliver Metzger
SESGL SES SA FDR (CLASS A)
RNO RENAULT SA
DAI DAIMLER AG
FGA FIGEAC AERO SA
LXS LANXESS AG
KCO KLOECKNER & CO SE
JCQ JACQUET METALS SA
BAMNB KONINKLIJKE BAM GROEP NV
GN GN STORE NORD A/S
SOLB SOLVAY SA
VOW3 VOLKSWAGEN AG PREF
GLB GLANBIA PLC
FIE FIELMANN AG
LNZ LENZING AG
DEZ DEUTZ AG
CFT COMPAGNIE FINANCIERE TRADITION
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
MELE MELEXIS NV
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
VGP VGP NV
11B 11 BIT STUDIOS S.A.
DIC DIC ASSET AG
WLN WORLDLINE SA
FNTN FREENET AG
GLPG GALAPAGOS NV
ATRY ATRYS HEALTH
INS INSTONE REAL ESTATE GROUP AG
S30 SOLUTIONS 30 SE
FSNT FASHIONETTE AG
STLA STELLANTIS N.V.
ANTIN ANTIN INFRASTRUCTURE PARTNERS
HGEA HGEARS AG
CTPNV CTP NV
FI-N GEORG FISCHER AG
VT5 VT5 ACQUISITION COMPANY AG
SHUR SHURGARD SELF STORAGE LIMITED
AF AIR FRANCE - KLM
- Emira Sagaama
- Hela Zarrouk
- Michael Foundoukidis
- Oliver Metzger
FGA FIGEAC AERO SA
LXS LANXESS AG
KCO KLOECKNER & CO SE
JCQ JACQUET METALS SA
BAMNB KONINKLIJKE BAM GROEP NV
GN GN STORE NORD A/S
SOLB SOLVAY SA
GLB GLANBIA PLC
FIE FIELMANN AG
LNZ LENZING AG
DEZ DEUTZ AG
CFT COMPAGNIE FINANCIERE TRADITION
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
MELE MELEXIS NV
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
VGP VGP NV
11B 11 BIT STUDIOS S.A.
DIC DIC ASSET AG
WLN WORLDLINE SA
FNTN FREENET AG
GLPG GALAPAGOS NV
ATRY ATRYS HEALTH
INS INSTONE REAL ESTATE GROUP AG
S30 SOLUTIONS 30 SE
FSNT FASHIONETTE AG
ANTIN ANTIN INFRASTRUCTURE PARTNERS
HGEA HGEARS AG
FI-N GEORG FISCHER AG
VT5 VT5 ACQUISITION COMPANY AG
SHUR SHURGARD SELF STORAGE LIMITED
AF AIR FRANCE - KLM
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Martial Descoutures
- Jacob Mekhael
Galapagos 9M25 results hold no surprises, new outlook following cell T...
Galapagos reported 9M25 results with a cash position of € 3,050m (YE24: € 3,317.8m) and an updated outlook, where it expects to end FY25 with € 2,975- € 3,025m in cash, and to incur costs of € 250-325m related to the winddown of the cell therapy business. Looking ahead, the company will focus its strategy on building a new pipeline through BD, and more information on BD strategy will be provided during this afternoon's conference call. € 37 TP and ACCUMULATE maintained.
Galapagos Reports Nine Months 2025 Financial Results and Provides Busi...
Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update Strategic review process concluded with intention to wind down cell therapy business, representing optimal capital allocation pathway to support a stronger and sustainable future for GalapagosContinued evolution of leadership team aligned with strategic directionRobust balance sheet with €3.05 billion in cash and financial investments as of September 30, 2025; year-end 2025 cash position expected at €2.975 billion to €3.025 billion Management to host a tomorrow, November 6, 2025, at 14:00 CET / 08:00 AM ET ...
Galapagos rapporteert financiële resultaten over de eerste negen maand...
Galapagos rapporteert financiële resultaten over de eerste negen maanden van 2025 en geeft bedrijfsupdate Strategisch evaluatieproces afgerond met de intentie om de celtherapieactiviteiten af te bouwen, wat de optimale kapitaalallocatie vertegenwoordigt ter ondersteuning van een sterkere en duurzame toekomst voor GalapagosVerdere ontwikkeling van het leiderschapsteam sluit aan bij de strategische richtingRobuuste balans met €3,05 miljard in geldmiddelen en financiële investeringen per 30 september 2025; verwachte kaspositie eind 2025 tussen €2,975 miljard en €3,025 miljardManagement organis...
- Jacob Mekhael
ASH abstracts: Autolus, Galapagos, MaaT
The abstracts for presentations at the American Society of Haematology conference (ASH, 6-9 December) became available yesterday during the day (HERE). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (new data for Aucatzyl in paediatric ALL, real world data in adult ALL, amongst others), Galapagos (additional CAR-T data in r/r MCL and r/r DLBCL) and MaaT (longer follow up from ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.